Wei Li
Cancer Research · with Chen · 2012–2015
A researcher in the Science corpus: 2 papers; trusts 3 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Cancer Research — 15 citations into it
- Molecular Biology — 14 citations into it
- Physiology — 5 citations into it
Whom Wei Li trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Wei Li's perspective
Ordered by how strongly the researchers Wei Li trusts endorse each paper. Same corpus, a different order for every researcher.
- HIF-1 and tumor progression: pathophysiology and therapeutics. (Trends in Molecular Medicine)
- HIF-1 and human disease: one highly involved factor. (Genes & Development)
- Targeting HIF-1 for cancer therapy (Nature Reviews. Cancer)
- A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF (Science)
- Hypoxia-inducible factor-1 (HIF-1). (Critical Care Medicine)
- Molecular mechanisms of blood vessel growth. (Cardiovascular Research)
- Hypoxia, HIF1 and glucose metabolism in the solid tumour (Nature Reviews. Cancer)
- HIF-1 and mechanisms of hypoxia sensing. (Current Opinion in Cell Biology)
- Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation (Science)
- Mechanism of regulation of the hypoxia‐inducible factor‐1α by the von Hippel‐Lindau tumor suppressor protein (EMBO Journal)
Their papers
- HIF-1α pathway: role, regulation and intervention for cancer therapy (2015) — 1,722 citations
- An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site (2012) — 694 citations